Click here to view the May 2023 edition of The Meeting Place.
News
The University of Birmingham’s Clinical Immunology Service (CIS) is soon to become the anchor tenant at the forthcoming Precision Health Technology Accelerator (PHTA), after signing up to occupy ~10,000 sq ft of the custom-built flagship research facility.
Providing a comprehensive range of accredited lab services to facilitate the diagnosis of autoimmune and neuroimmunological disease, blood cancers, primary and secondary immunodeficiency, infections and allergy, the CIS receives more than 100,000 blood, marrow, urine and other samples per year.
Early-stage life sciences enterprises are set to benefit from a unique new collaboration between Birmingham’s Precision Health Technologies Accelerator (PHTA) and Oxford Science Enterprises (OSE).
The partnership will focus on helping high-growth health technology and life sciences companies to scale, primarily through access to high-quality lab and innovation space, while also catalysing cross-regional collaboration between academics and enterprises.
Stevenage, 18th May, 2023 – Kadans Science Partner (Kadans), the European leader in developing science and technology real estate, today announces the launch of Sycamore House, a new laboratory and office facility for innovative, high-growth life science companies and Kadans’ first completed development in the UK. By adding Sycamore House to the portfolio, Kadans is furthering its goal to create one strong knowledge-sharing ecosystem of science parks across Europe.
- Pharmanovia’s leading medicine brands to be combined with Closed Loop Medicine’s technology to provide dose optimized personalized therapies
- Global (ex-US) co-development and commercialization partnership to initially focus on next-generation drug + software product solutions for the treatment of hypertension
Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort
Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has launched a new in vitro model of the blood brain barrier (BBB) for research into neurodegenerative diseases.
London and Oxford, UK, 15 May 2023 – Self funded, not-for-profit medical research organisation LifeArc and techbio company PrecisionLife announce a strategic R&D collaboration to accelerate the discovery and development of targeted treatments for motor neuron disease (MND) - also known as amyotrophic lateral sclerosis (ALS), and Lou Gehrig's disease.
- First delivery and use of DNA manufactured using Evonetix's unique thermally controlled synthesis technology
- Key milestone in the development of Evonetix's desktop DNA synthesis platform